Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Tolerability of Eloralintide in Participants With Hepatic Impairment
NCT07401862Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2026
- Primary completion
- Mar 2027
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 1, open-label trial of eloralintide (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Zero to Infinity and Maximum Observed Drug Concentration. Started Feb 2026; status: recruiting.
02
Drugs
eloralintide
Beyond the preview
Go deeper on NCT07401862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07401862.